eng Science and Education Publishing American Journal of Medical Case Reports 2374-216X 2016-12-09 4 11 361 363 10.12691/ajmcr-4-11-3 AJMCR20164113 article Bala Basak Oven Ustaalioglu basakoven@yahoo.com 1 Recep Ustaalioglu MD 2 Mehmet Yildirim 2 Medical Oncology, Haydarpasa Numune Educatio and Research Hospital ThoracicSurgery Siyami Ersek Education and Research Hospital, Istanbul, Turkey Objectives: Venous port catheter has been currently used in chemotherapy especially for colon cancer patients. Venous thrombosis related with venous device is frequently reported but superior vena cava syndrome(svc) with high mortality rate is rarely seen as a port catheter related thrombosis. Cetuximab which has been used in metastatic colon cancer is an anti-EGFR agent has shown to be risk factor for venous thromboembolic events. Patients: Inhere we reported 2 metastatic colon cancer patients who had been treated with chemotherapy combined with cetuximab via venous port catheter. Svc was detected in both of them during therapy with cetuximab. None of them had any co-morbidity or tendency for thrombosis. Cetuximab is thought to be increase thrombosis and may cause the svc syndrome. Conclusion: When metastatic colon cancer patients presented with redness and swelling of face while they receiving cetuximab via venous port catheter, other than allergic reaction, superior vena cava syndrome also should keep in mind. http://pubs.sciepub.com/ajmcr/4/11/3/ajmcr-4-11-3.pdf superior vena cava syndrome port catheter cetuximab thrombosis cancer